ResearchHow I treat patients with CLL after prior treatment with a covalent BTK inhibitor and a BCL-2 inhibitor
ResearchOpportunities to Improve Antibiotic Stewardship, and Identification of Blood Biomarkers Associated with Bacteremia Following CAR-T Cell Therapy
ResearchZanubrutinib in the treatment of patients with del(17p) and/or TP53 CLL/SLL: analysis across clinical studies
ResearchDigital pathology and image analysis of p53 biomarker in lymphomas using two algorithms: correlation with genotype and visual inspection
ResearchImpact of Gamma-Secretase Inhibition on Outcomes Following BCMA CAR-T Therapy in Multiple Myeloma: A Comparison of Two Phase 1 Trials
ResearchImpact of immunophenotype on clinical disease characteristics and outcomes in T-cell prolymphocytic leukaemia
ResearchDevelopment and validation of a gene expression signature to predict early events in patients with follicular lymphoma
ResearchLong-term follow-up of dose-dense brentuximab vedotin, ifosfamide, carboplatin and etoposide in second-line treatment of relapsed/refractory classical Hodgkin lymphoma
ResearchWho Is Eligible for Chimeric Antigen Receptor T Cell Therapy? Expert Perspectives on Overcoming Referral Barriers
ResearchCRS or ICANS Are Rare Beyond 2 Weeks After Lisocabtagene Maraleucel Infusion: Data From Clinical Trials and the Real-World Setting
ResearchBarriers to Investigator-Initiated Clinical Trial Enrollment in Frontline Large B-Cell Lymphoma